Genzyme, a Sanofi company, announced today that the British Columbia drug program, PharmaCare, has included Aubagio (teriflunomide) 14 mg on the provincial formulary as a first-line oral agent for people in the province living with relapsing remitting multiple sclerosis (RRMS). 

Aubagio is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

"We are pleased to have an additional therapy available to us in the treatment of MS. Having access to this new oral therapy will allow us to tailor our treatment to our patients' needs. We are grateful to the provincial drug program in BC for approving access to this therapy in 1st line," said Dr. Virginia Devonshire, Clinical Assistant Professor Neurology, UBC. 

"It is important that British Columbians living with MS are able to access the full range of treatment options in consultation with their healthcare team," says Tania Vrionis, President of the MS Society, BC & Yukon Division. "The availability of therapies that can be administered orally – especially as 'first line options' – is a welcome development. The MS Society is pleased that the provincial government continues to provide coverage of MS treatments in a timely manner."

For more details, go to: http://www.newswire.ca/en/story/1461941/british-columbia-funds-treatment-with-aubagiotm-for-relapsing-remitting-multiple-sclerosis